Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer (Review).

International journal of oncology - 1 Nov 2021

He Jingyi, Huang Zhengrong, Han Linzhi, Gong Yan, Xie Conghua

Abstract excerpt

Targeted therapy with epidermal growth factor receptor (EGFR)‑tyrosine kinase inhibitors (TKIs) is a standard modality of the 1st‑line treatments for patients with advanced EGFR‑mutated non‑small cell lung cancer (NSCLC), and substantially improves their prognosis. However, EGFR T790M mutation is the primary mechanism of 1st‑ and 2nd‑generation EGFR‑TKI resistance. Osimertinib is a representative of the...

Topics

Join the communities discussing this publication.

Bcl-2-Like Protein 11
Carcinoma, Non-Small-Cell Lung
Drug Resistance, Neoplasm
ErbB Receptors
Immune Checkpoint Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Protein Kinase Inhibitors

Signal Transduction

Source

Open in PubMed Open full text

Identifiers

PMID: 34558640
DOI: 10.3892/ijo.2021.5270
PMCID: PMC8562388

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer (Review).PMID 34558640Read ↗

Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies.Semantic proximity Read ↗

Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic StrategiesSemantic proximity Read ↗

Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer.Semantic proximity Read ↗

Resistance to EGFR Inhibitors in NSCLC: Mechanistic Insights and Emerging Therapies.Semantic proximity Read ↗

Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?Semantic proximity Read ↗

Treatment in EGFR-mutated non-small cell lung cancer: how to block the receptor and overcome resistance mechanisms.Semantic proximity Read ↗

Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies.Semantic proximity Read ↗

Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy.Semantic proximity Read ↗

Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.Semantic proximity Read ↗

Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.Semantic proximity Read ↗

EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.